Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Subviral Agents01:29

Subviral Agents

589
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
589
Air-entraining Agents01:27

Air-entraining Agents

278
Air-entraining agents improve the durability and workability of concrete in climates with frequent freezing and thawing. These agents prevent cracks by introducing small air bubbles into the mix, creating spaces accommodating water expansion when temperatures drop. The air-entraining agents lower the surface tension of water, forming stable, small air bubbles. This method is more effective than having accidental large voids, as the intentional, smaller, and evenly distributed air voids improve...
278
Masking and Demasking Agents01:19

Masking and Demasking Agents

3.7K
EDTA titrations may necessitate masking and demasking agents to temporarily protect a particular metal ion in a mixture from the EDTA reaction. These agents facilitate the sequential analysis of the metal ions by forming stable complexes with some—but not all—metal ions during certain steps.
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on...
3.7K
Spasmolytic Agents: Chemical Classification01:29

Spasmolytic Agents: Chemical Classification

1.3K
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

695
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
695
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

1.2K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Standardizing the Clinical Approach to Cancer Therapy-Related Cardiac Dysfunction: Applying Cardio-Oncology Guidelines as a Practical Tool for Hematology and Oncology Providers.

Cancer medicine·2026
Same author

Supporting Family Caregiver Health in Heart Failure: Longitudinal Associations Between Heart Failure Caregiver Self-Care and Patient Hospitalizations.

Journal of cardiac failure·2026
Same author

Research Priorities and Future Directions in Cardio-Oncology.

Current treatment options in oncology·2026
Same author

Timing of inotropic support is associated with mortality in patients with acute decompensated heart failure-associated cardiogenic shock.

Intensive care medicine experimental·2025
Same author

Observational Study of Sublingual Microcirculation in Patients With Chronic Cardiovascular Disease.

Microcirculation (New York, N.Y. : 1994)·2025
Same author

Impact of Cardiac Radiation Dose on Cardiotoxicity in Patients With Breast Cancer Undergoing Adjuvant Trastuzumab Therapy.

International journal of radiation oncology, biology, physics·2025
Same journal

Diagnostic Tests for Stage B Heart Failure.

Current cardiology reports·2026
Same journal

Cardioimmunology of Myocarditis: Targeting the IL-1 Pathway.

Current cardiology reports·2026
Same journal

Antithrombotic Management in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.

Current cardiology reports·2026
Same journal

Transcriptome Reprogramming in Heart Failure: The Hidden Splicing Code.

Current cardiology reports·2026
Same journal

Diagnosis and Management of Loeys-Dietz Syndrome: Evidence Gaps and Future Directions.

Current cardiology reports·2026
Same journal

Correction: Heart Disease in Older Women: Unique Challenges in Diagnosis and Management.

Current cardiology reports·2026
See all related articles

Related Experiment Video

Updated: Feb 13, 2026

Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs
08:19

Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs

Published on: July 12, 2022

3.5K

Left Ventricular Dysfunction and Chemotherapeutic Agents.

Suparna C Clasen1, Joyce W Wald2

  • 1Cardio-oncology in the Division of Cardiology, Hospital of the University of Pennsylvania, 3400 Civic Center Boulevard, South Pavilion 11th Floor, Philadelphia, PA, 19104, USA. Suparna.clasen@uphs.upenn.edu.

Current Cardiology Reports
|March 10, 2018
PubMed
Summary
This summary is machine-generated.

Cancer therapies can cause heart problems, specifically left ventricular (LV) dysfunction. Early detection and treatment of cardiotoxicity are crucial for managing heart failure in cancer patients.

Keywords:
Cancer therapy-related cardiotoxicityCardio-oncologyChemotherapyHeart failureLV dysfunction

More Related Videos

Evaluation of Left Ventricular Structure and Function using 3D Echocardiography
06:34

Evaluation of Left Ventricular Structure and Function using 3D Echocardiography

Published on: October 28, 2020

4.7K
Transthoracic Speckle Tracking Echocardiography for the Quantitative Assessment of Left Ventricular Myocardial Deformation
09:05

Transthoracic Speckle Tracking Echocardiography for the Quantitative Assessment of Left Ventricular Myocardial Deformation

Published on: October 20, 2016

20.2K

Related Experiment Videos

Last Updated: Feb 13, 2026

Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs
08:19

Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs

Published on: July 12, 2022

3.5K
Evaluation of Left Ventricular Structure and Function using 3D Echocardiography
06:34

Evaluation of Left Ventricular Structure and Function using 3D Echocardiography

Published on: October 28, 2020

4.7K
Transthoracic Speckle Tracking Echocardiography for the Quantitative Assessment of Left Ventricular Myocardial Deformation
09:05

Transthoracic Speckle Tracking Echocardiography for the Quantitative Assessment of Left Ventricular Myocardial Deformation

Published on: October 20, 2016

20.2K

Area of Science:

  • Cardio-oncology
  • Cardiovascular medicine
  • Oncology

Background:

  • Cancer therapeutics can induce acute and delayed cardiotoxicity.
  • Left ventricular (LV) dysfunction may precede clinical heart failure (HF) symptoms.
  • Monitoring for cardiotoxicity is essential in cancer patients.

Purpose of the Study:

  • To summarize the impact of cancer therapy-related cardiotoxicity on LV dysfunction.
  • To review early detection, treatment, and prevention strategies for cardiotoxicity.

Main Methods:

  • Review of commonly used cancer therapeutics and their cardiotoxic potential.
  • Discussion of multi-modality imaging for early toxicity detection (e.g., echocardiographic strain techniques).
  • Evaluation of biomarkers for LV dysfunction detection.
  • Analysis of current monitoring and treatment approaches, including risk factor modification and neurohormonal blockade (NHB).

Main Results:

  • LV dysfunction can be detected by cardiac imaging before HF symptoms arise.
  • Advanced echocardiography and biomarkers aid in early toxicity identification.
  • Management involves addressing cardiovascular risk factors, initiating NHB (beta-blockers, RAAS inhibitors), and guideline-directed therapy.
  • Advanced therapies like mechanical resynchronization, ventricular assist devices, and transplantation are used for severe cases.

Conclusions:

  • Early detection and intervention are key to managing LV dysfunction from cancer therapy.
  • A multi-faceted approach combining risk factor management, pharmacotherapy, and advanced HF treatments is vital.
  • Preventing and treating cardiotoxicity improves outcomes for cancer patients.